Quantum BioTarget™ – White Paper

Targeting Cancer at the Speed of Entanglement™

Founder: Adam Samuel McCombs | Email: founder@quantumbiotarget.com

1. Executive Summary

Quantum BioTarget™ introduces a novel cancer therapy platform that leverages entangled photons for targeting, nanodiamonds for delivery, and AI for intelligent control. This integrated system is designed to deliver alpha-emitting isotopes directly into cancer cells with unprecedented accuracy, minimizing damage to surrounding tissue

2. The Challenge of Precision in Cancer Therapy

Traditional cancer treatments lack targeting specificity, often leading to collateral damage to healthy tissue. Therapies like chemotherapy, radiation, and even immunotherapy frequently affect non-cancerous cells, resulting in toxicity and long-term side effects.

3. The Quantum BioTarget™ Solution

We combine three cutting-edge technologies: 1) entangled photons for sub-cellular navigation, 2) Bi-213-loaded nanodiamonds for therapeutic delivery, and 3) Ontria AI for dual-trigger activation and adaptive learning. This system improves delivery accuracy, reduces immune response, and provides real-time confirmation of dose delivery.



4. Entangled Photon Targeting Explained

Entangled photons are generated via SPDC and directed using beam splitters. One path goes to the tumor site, while its entangled pair confirms arrival via real-time photon verification. This method ensures that payload delivery is precisely targeted and validated.

5. Nanodiamonds as Payload Carriers

Nanodiamonds are chosen for their biocompatibility, low toxicity, and ease of functionalization. They can be coated to recognize tumor receptors or respond to environmental triggers like acidic pH or elevated temperature. They also serve as carriers for radioactive payloads such as Bi-213.

6. The Bi-213 Payload

Bismuth-213 is an alpha-emitting isotope ideal for killing cancer cells due to its high energy and short range. When released inside or near the tumor, it delivers lethal radiation with minimal risk to nearby healthy cells.

7. Ontria AI – Dual-Trigger Logic System

Ontria AI governs the final payload release, using both quantum and biological data streams. It filters false positives using photon hits, receptor data, and environmental inputs. This ensures precision before activating payload deployment, preventing premature or incorrect release.

8. Immune Response Mitigation

To avoid immune system activation, nanodiamonds are coated with stealth materials (e.g., PEG) that allow them to circulate longer without being flagged as foreign. This increases delivery time and reduces clearance by the liver or spleen.

9. Real-Time Dosimetry & Safety

Each successful photon verification and payload release is logged, enabling feedback-driven treatment optimization. This allows doctors to monitor effective dose levels without overexposure.

10. Manufacturing Strategy & Cost Model

The system will be built using micro-batch nanodiamond synthesis and isotope handling under cleanroom conditions. Anticipated cost per dose in early phases is high but drops significantly with volume scaling.

11. Competitive Landscape

Quantum BioTarget fills a gap left by conventional methods like CAR-T and monoclonal antibodies, which struggle with solid tumors and precision delivery. Our platform offers non-invasive, high-precision therapeutic alternatives.

12. Preclinical Testing Roadmap

Initial validation will begin with in-vitro cell targeting and delivery, followed by in-vivo studies using murine cancer models. Post efficacy and toxicity trials, we move to primate studies before FDA engagement.

13. Grant Funding & Investment Strategy

Primary targets include NCI/NIH grants under SBIR/STTR programs. Investment rounds will prioritize R&D completion, regulatory filing, and prototype development with clinical partners.

14. Lab-to-Miniaturization Roadmap

The initial benchtop validation prototype will evolve into a compact unit through precision microengineering, aiming for potential catheter or implant-based delivery platforms in phase II.

15. Founder Background

Adam Samuel McCombs, a visionary inventor driven by personal loss and a mission to end cancer's collateral damage. Despite a non-traditional background, Adam's relentless innovation brought Quantum BioTarget to life.

16. Expanded Q&A / Anticipated Questions

Q1: How does Quantum BioTarget™ differ from conventional cancer therapies?

A: Unlike traditional chemotherapy or radiation, Quantum BioTarget™ leverages entangled photons for precision targeting and AI-regulated dual-trigger release of Bismuth-213-laced

nanodiamonds. This method significantly reduces off-target effects, increases tumor specificity, and enables real-time feedback using quantum signaling mechanisms.

Q2: Is this technology proven, or is it still theoretical?

A: Each core component has strong scientific precedent:

- **Entangled photon generation and transmission** is widely demonstrated in labs.
- **Nanodiamonds as drug carriers** are actively researched and used in targeted delivery.
- **Bismuth-213** is FDA-designated for cancer radiotherapy.
  The integration of these into a unified, AI-controlled, precision-guided therapy is novel—and the subject of our current patent and development effort.

Q3: What if the photon targeting fails or misses?

A: The system includes built-in fail-safes:

- **Dual-trigger logic** (AI + quantum verification) ensures the payload is only released upon confirmed tumor presence.
- **Ontria AI** continuously learns from prior data and adjusts logic thresholds to prevent false positives.
- In the worst case, nanodiamonds will not release payloads without both triggers being satisfied.

Q4: Is a prototype currently available?

A: A working **3D software simulation** is underway and scheduled for preview by **September 8, 2025**. Hardware development will follow in partnership with academic or biotech labs. Prototype miniaturization is outlined in our "Lab-to-Field" roadmap section.

Q5: Will this technology work on all cancer types?

A: While initial targeting focuses on **solid tumors** with accessible receptor markers (e.g., prostate, breast, glioblastoma), the platform is modular and can adapt to different cancer environments via:

- Tumor microenvironment sensing (pH, temperature)
- Imaging-integrated logic
- Payload customization per cancer type

Q6: How does Ontria AI make decisions?

A: Ontria monitors:

- Imaging data (X-ray/CT inputs)
- Photon verification feedback
- Biomarker signal thresholds
  It uses **reinforcement learning** to refine its logic gates and ensures only verified targets initiate release, reducing the likelihood of collateral damage.

Q7: How do you prevent immune rejection or toxicity from nanodiamonds?

A: Nanodiamonds are:

- Biocompatible and FDA-reviewed
- Easily functionalized with stealth coatings (e.g., PEGylation)
- Cleared by renal filtration after degradation
  We also ensure minimal payload size and delayed-release logic to reduce systemic burden.

Q8: What regulatory path do you anticipate?

A: We plan a **Class III device** designation via the FDA, under the **combination product** pathway. Milestones include:

- Preclinical validation (2025–2026)
- Phase 1 safety (2026–2027)
- Fast-track designation due to unmet need in inoperable tumors

---

Q9: What is the projected cost of manufacturing this system?

A: Initial lab-scale production cost is estimated at **$5,000–$10,000/unit**, with miniaturized mass production expected to drop below **$500/unit**. Key drivers include nanomaterial synthesis, entanglement optics, and control electronics.

Q10: Will external interference affect the quantum signals?

A: Quantum verification uses **entangled photon authentication**, which makes tampering or noise injection detectable and self-correcting. Signals are tested for collapse or mismatched polarization as a security layer before payload activation.7. Collaboration & Licensing Invitation

We welcome universities, national labs, venture partners, and biotech firms to join us in advancing this technology. Licensing, co-development, or research partnerships are open for discussion.

Immune Response Mitigation Strategy

To minimize immune response to nanodiamond carriers or isotope payloads, Quantum BioTarget™ employs biocompatible surface coatings and size optimization. Preclinical validation includes monitoring cytokine profiles and histopathological response to ensure minimal systemic inflammation or immune rejection.

Cost Model and Manufacturing Pathway

Initial nanodiamond synthesis and Bi-213 isotope handling require lab-scale cleanroom infrastructure and radiation shielding. Projected costs decrease with scaled automated manufacturing. Targeted partnerships with nanotech and radiopharmaceutical facilities will support GMP-compliant production. Estimated unit cost (Phase I prototype) ranges from $2,000–$5,000.

Lab-to-Miniaturization Roadmap

Following successful preclinical validation, the Quantum BioTarget™ system will transition to a portable, cable-sized delivery device. Miniaturization of entanglement generation optics, AI processor (Ontria), and shielding will be guided by photonic integration breakthroughs. Roadmap milestones include: (1) functional benchtop system, (2) mobile unit prototype, (3) hand-held integration.

Photon Verification and Control Logic

Entangled photons serve not only as targeting guides but also as authentication pulses. The system confirms successful targeting by detecting the arrival of entangled twin photons at the tumor site. These logic confirmations trigger Ontria's decision to release the payload, providing real-time verification of targeting precision.

For deeper technical documentation, simulation preview access, or partner materials — please request an NDA from
founder@quantumbiotarget.com